Biognosys provides innovative services and products for protein discovery and quantification using cutting edge technology, providing one of the best solutions to support researchers in their protein analysis needs.
Biognosys – next-generation proteomics
Biognosys’ next generation technology quantifies proteins with unbeatable precision and depth. The solution is based on mass spectrometry based targeted proteomics technology, which provides simultaneous quantification for thousands of proteins in a single experiment. The goal in mass spectrometry based proteomics is to identify and quantify proteins in complex biological matrices with high sensitivity and precision. Compared to classical analytical chemistry the challenge is the complexity of proteomes in natural samples, where typically 100’000s of peptides are present, spanning several orders of magnitude in abundance. Different mass spectrometric approaches have been developed in the past to resolve this challenge. Next-generation proteomics outperforms the classical approaches and has started to transform protein science just as next-gen sequencing has transformed genomics. The difference to older approaches (e.g. shotgun proteomics) is in the method how the mass spectrometer acquires the signals and in the signal processing algorithms: sequential acquisition is replaced with parallel acquisition.
HRM-MS (Hyper Reaction Monitoring-MS) is the next generation high-content proteomics technology invented at Biognosys that enables reproducible and precise quantification of 1000s of proteins in a single instrument run with data independent acquisition (DIA). The acquired signals are analyzed with Biognosys’ proprietary software Spectronaut using large spectral libraries as templates for highly specific detection and quantification. The result is a simple and complete data matrix with precise quantity values for each protein in each sample, which can be interpreted by any researcher without the need for expert knowledge.
Biognosys was founded in 2008 and is a privately held company in Zurich (Switzerland). Originally an ETH Zurich spin-off from the lab of Prof. Ruedi Aebersold, Biognosys is a pioneer in the field of proteomics and caters to the Pharma, Biotech, Diagnostics and Agricultural industries. Management Team is composed by Oliver Rinner, Lukas Reiter, Claudia Escher and Stephan van Sint Fiet. Board of Directors is composed by Michael Sidler, Derek Norman, Winfried Mayer and Harry Welten. Scientific Advisory Board is composed by Ruedi Aebersold, Johan Malmstroem and Paola Picotti. Biognosys continuously develops its protein-quantification technology to provide the best possible results for its customers. Whether the aim is biomarker discovery, drug target validation, or mode of action studies, Biognosys’ methodology and equipment are consistently at the leading edge.
More about Biognosys : www.biognosys.ch